Nevakar Injectables Announces FDA Approval of Cyclophosphamide RTD Solution
03. Juli 2023 08:00 ET
|
Nevakar, Inc.
-- Ready-to-dilute, multi-dose vials reduce compounding time and waste -- BRIDGEWATER, N.J., July 03, 2023 (GLOBE NEWSWIRE) -- Nevakar Injectables Inc. (“Nevakar”), a biopharmaceutical company...
Vyluma and Laboratoires Théa Enter into Licensing Agreement for the Registration and Commercialization of NVK002 in Canada, Mexico, and Select South American Countries
14. Juni 2022 07:30 ET
|
Nevakar, Inc.
BRIDGEWATER, N.J., June 14, 2022 (GLOBE NEWSWIRE) -- Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets in the ophthalmic space for the treatment of refractive errors,...
Nevakar Injectables Sells Six Development-Stage, Ready-to-Use Injectable Product Candidates to Endo Ventures Limited
02. Mai 2022 07:30 ET
|
Nevakar, Inc.
BRIDGEWATER, N.J., May 02, 2022 (GLOBE NEWSWIRE) -- Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile...
Nevakar Injectables Receives U.S. FDA Approval of Ready-to-Use Ephedrine Injection in a Prefilled Syringe
28. April 2022 07:30 ET
|
Nevakar, Inc.
BRIDGEWATER, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile...
Nevakar Injectables Announces the Launch of Ready-to-Use Ephedrine Injection Vials
28. März 2022 07:30 ET
|
Nevakar, Inc.
BRIDGEWATER, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Nevakar Injectables Inc., a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory...
Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest-Only Period with Oxford Finance
09. März 2022 12:14 ET
|
Nevakar, Inc.
BRIDGEWATER, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it...
Nevakar and Théa Enter into Licensing Agreement for the Commercialization of NVK-002 (Atropine for the Treatment of the Progression of Myopia in Children) in Europe
28. Januar 2021 06:50 ET
|
Nevakar, Inc.
-- Potential to receive up to $135 million upon the successful attainment of several key regulatory and sales milestones -- BRIDGEWATER, N.J. and CLERMONT-FERRAND, France, Jan. 28, 2021 (GLOBE...
First Patient Completes Three Year Enrollment in Nevakar’s Phase III CHAMP Study of NVK-002 Evaluating Low-Dose Atropine Ophthalmic Solution for the Treatment of Myopia in Children
09. November 2020 07:00 ET
|
Nevakar, Inc.
BRIDGEWATER, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nevakar Inc., a biopharmaceutical company developing multiple products in the ophthalmic and injectable areas, announced today that the first...
Nevakar Announces FDA Approval for Ephedrine Sulfate Injection as Ready-to-Use Vials
22. Oktober 2020 07:00 ET
|
Nevakar, Inc.
BRIDGEWATER, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today it received approval...
Nevakar Enters $50 Million Product Financing Agreement with NovaQuest Capital for Continued Development of Injectable Products
18. Juni 2019 08:00 ET
|
Nevakar, Inc.
BRIDGEWATER, N.J. and RALEIGH, N.C., June 18, 2019 (GLOBE NEWSWIRE) -- Nevakar Inc. (“Nevakar” or the “Company”), a specialty pharmaceutical company developing multiple assets in the ophthalmic and...